Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00905515 · ClinicalTrials.gov registry record · Phase 4
Optima: Optimizing Prograf Therapy in Maintenance Allografts II
A Phase 4 study, sponsored by East Carolina University.
- Completed
- Registry status
- Phase 4
- Development phase
- 63
- Enrollment target
NCT00905515 is a Phase 4 study that has completed, run by East Carolina University. The registered enrollment target is 63 participants.
The verdict
NCT00905515, a Phase 4 study, has completed, sponsored by East Carolina University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 63 participants
- Enrollment target
Study Summary
This study is designed to optimize calcineurin immunosuppressive regimens and evaluate immunological and non-immunological markers that may explain mechanistic differences in these agents and their effects.
Interventions
- DRUG cyclosporine
- DRUG Prograf (Tacrolimus)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2003-08 |
| Est. Completion | 2008-07 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00905515
The ClinicalTrials.gov registry entry for NCT00905515 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 63 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is East Carolina University, which has 58 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which cyclosporine is the first listed.
NCT00905515 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00905515 about?
NCT00905515 is a clinical study titled "Optima: Optimizing Prograf Therapy in Maintenance Allografts II". This study is designed to optimize calcineurin immunosuppressive regimens and evaluate immunological and non-immunological markers that may explain mechanistic differences in these agents and their effects.
What is the current status of trial NCT00905515?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 63 participants. The study started on 2003-08. Estimated completion is 2008-07.
What interventions are being tested in trial NCT00905515?
The interventions under investigation include: cyclosporine (DRUG), Prograf (Tacrolimus) (DRUG).
Who is sponsoring clinical trial NCT00905515?
This trial is sponsored by East Carolina University, which has 58 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.